PMNProMIS Neurosciences Inc. Common Shares (ON)

CSNasdaq (XNAS)·USD

Identity

Security key: 20232
Ticker: PMN
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2005-09-30
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: PMN

Detail

Enriched 2026-08-14 20:47

Market cap: $130,031,548.5
Shares outstanding (class): 8,967,693
Shares outstanding (weighted): 8,967,693
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 11
Location: TORONTO, A6
Homepage: https://www.promisneurosciences.com
Description: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Market cap and share counts drift.

Funds holding this security

1 funds · 1 positions · -$5.1K reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds	—	-$5.1K	-0.00%	-404 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERPMN
FIGI_COMPOSITEBBG000R0MF47
FIGI_SHARE_CLASSBBG001SMDG62
CIK0001374339
ISINCA74346M5054
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: ProMIS Neurosciences is a biotech company developing therapeutics for neurodegenerative diseases, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.